Cleveland BioLabs (CBLI) gapped up at the open Monday and has risen sharply in early trade on the highest volume of the year. Shares are now up 0.83 at $2.39. The stock has surged to an 8-month high.
Cleveland BioLabs announced this morning that the European Medicines Agency has accepted its pediatric investigation plan for entolimod as a medical radiation countermeasure.
The FDA has also finished its review of a side-by-side analytical comparison of two formulations of entolimod. The FDA has consented to the initiation of an in vivo biocomparability study of these formulations in non-human primates.
by RTT Staff Writer
For comments and feedback: email@example.com